Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Giardiasis01:12

Giardiasis

Giardiasis is a globally prevalent intestinal infection caused by the protozoan parasite Giardia duodenalis (also known as G. lamblia or G. intestinalis). This flagellated protozoan is the most frequently identified intestinal parasite in the United States and worldwide. Transmission primarily occurs via the fecal-oral route, with infection arising from ingestion of water or food contaminated with cysts. Individuals in low-resource settings, international travelers, outdoor enthusiasts, daycare...
Bacterial Gastroenteritis01:18

Bacterial Gastroenteritis

Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial.

United European gastroenterology journal·2026
Same author

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Alimentary pharmacology & therapeutics·2026
Same author

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial.

Gut·2026
Same author

Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumab.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Calling for Diversity: Improving Transfusion Safety Through High-Throughput Blood Group Microarray Genotyping.

Genomics, proteomics & bioinformatics·2026
Same author

MARCO promotes cholangiocarcinogenesis by inducing immunosuppression and its targeting reduces tumor growth.

Signal transduction and targeted therapy·2026
Same journal

ENDOSCOPIC REMOVAL OF BONE FOREIGN BODY EMBEDDED IN THE COLON.

Gastroenterologia y hepatologia·2026
Same journal

An uncommon endoscopic finding: esophageal intramural pseudodiverticulosis.

Gastroenterologia y hepatologia·2026
Same journal

Anemia and Hypoalbuminemia are Associated with Hepatic Encephalopathy and Mortality after Portal Hypertension-Related Bleeding.

Gastroenterologia y hepatologia·2026
Same journal

Optimization of a mobile application for the management of hepatitis D based on patient experience: an observational study in a hepatology cohort.

Gastroenterologia y hepatologia·2026
Same journal

Assessment of Training in Pancreatology and Biliary Diseases During Gastroenterology Residency: A National Survey by AEG-AESPANC.

Gastroenterologia y hepatologia·2026
Same journal

HEPATOCELLULAR CARCINOMA SURVEILLANCE: A PRACTICAL GUIDEBASED ON CURRENT EVIDENCE.

Gastroenterologia y hepatologia·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

[Clostridium-difficile-associated diarrhea].

Luis Bujanda1, Angel Cosme

  • 1Servicio de Aparato Digestivo, Hospital Donostia, Centro de Investigación Biomédica en Enfermedades Hepáticas y Digestivas (CIBEREHD), San Sebastián, España. medik@telefonica.net

Gastroenterologia Y Hepatologia
|January 29, 2009
PubMed
Summary
This summary is machine-generated.

Clostridium difficile infection causes frequent nosocomial diarrhea, with a hypervirulent strain (NAP1/BI/027) emerging. Diagnosis involves toxin detection, and treatment includes antibiotics or surgery, though relapse is common.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Experiment Videos

Last Updated: Jun 26, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

  • Infectious Diseases
  • Gastroenterology
  • Hospital Epidemiology

Background:

  • Clostridium difficile is a leading cause of hospital-acquired diarrhea.
  • Inflammation results from a non-specific host response to bacterial toxins.
  • A hypervirulent strain, NAP1/BI/027, has increased disease severity and incidence.

Purpose of the Study:

  • To review the epidemiology, diagnosis, treatment, and prevention of Clostridium difficile infections.
  • To highlight the challenges posed by the hypervirulent NAP1/BI/027 strain.

Main Methods:

  • Literature review of Clostridium difficile infection (CDI) diagnosis and management.
  • Discussion of clinical presentation, diagnostic methods (toxin detection, colonoscopy).
  • Overview of therapeutic options including antibiotics (metronidazole, vancomycin) and surgical intervention (subtotal colectomy).

Main Results:

  • Nosocomial diarrhea is frequently caused by Clostridium difficile.
  • Symptoms include abdominal pain and diarrhea, often linked to antibiotic use.
  • Relapse rates are high, necessitating differentiation from reinfection.

Conclusions:

  • Early diagnosis and appropriate treatment are crucial for managing Clostridium difficile infection.
  • Effective prevention and control strategies are essential in healthcare settings.
  • The emergence of hypervirulent strains necessitates ongoing vigilance and research.